<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00858117</url>
  </required_header>
  <id_info>
    <org_study_id>NU 04H6</org_study_id>
    <secondary_id>NU 04H6</secondary_id>
    <secondary_id>STU00004494</secondary_id>
    <nct_id>NCT00858117</nct_id>
  </id_info>
  <brief_title>A Phase II Trial of Alemtuzumab and Rituximab in Patients With Previously Untreated CLL</brief_title>
  <official_title>A Phase II Trial of Alemtuzumab (Campath-1H) and Rituximab (Rituxan) in Patients With Previously Untreated CLL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies, such as alemtuzumab and rituximab, can block cancer growth&#xD;
      in different ways. Some block the ability of cancer cells to grow and spread. Others find&#xD;
      cancer cells and help kill them or carry cancer-killing substances to them. Giving&#xD;
      alemtuzumab together with rituximab may kill more cancer cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying the side effects of giving alemtuzumab together with&#xD;
      rituximab and to see how well it works in treating patients with previously untreated B-cell&#xD;
      chronic lymphocytic leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  To determine the response rate in patients with previously untreated B-cell chronic&#xD;
           lymphocytic leukemia treated with alemtuzumab and rituximab.&#xD;
&#xD;
        -  To evaluate the toxicity of alemtuzumab and rituximab in these patients.&#xD;
&#xD;
      OUTLINE: Patients receive alemtuzumab subcutaneously on days 1, 3, and 5 in weeks 1-18 and&#xD;
      rituximab IV on day 1 in weeks 3, 5, 7, 9, 11, 13, 15, and 17 in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      Peripheral blood and bone marrow samples are collected periodically for laboratory biomarker&#xD;
      studies. Samples are analyzed for surface markers (e.g., CD3, CD4, CD8, CD10, CD19, CD20,&#xD;
      CD25, CD38, CD52, Zap-70) and IgVH by PCR, flow cytometry, and FISH. Samples are also&#xD;
      analyzed for alemtuzumab and anti-alemtuzumab antibody levels by flow cytometry.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically for 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 26, 2005</start_date>
  <completion_date type="Actual">January 24, 2013</completion_date>
  <primary_completion_date type="Actual">March 17, 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients Treated With Alemtuzumab and Rituximab Combination With a Response (CR or PR) Assessed by NCI-WG 1996 Criteria With Lymph-adenopathy and Organomegaly Measured During Physical Examination</measure>
    <time_frame>At week 9, and post-18 weeks then every 3 months for a year and up every 6 months for up to 2 years</time_frame>
    <description>Response rate (complete remission(CR) + partial remission(PR)) will be, assessed by NCI-WG 1996 criteria with lymphadenopathy and organomegaly measured during physical examination.&#xD;
CR=Absence of lymphadenopathy and constitutional symptoms, Normal CBC (leukocytes ≥ 1500/μl, Platelets &gt;100,000/μl, Hemoglobin &gt; 11.0 gm/dl), peripheral blood lymphocytes ≤ 4,000/μl.The marrow sample must be at least normocellular with &lt; 30% of nucleated cells being lymphocytes.&#xD;
PR=absence of constitutional symptoms, ≥ 50% decrease in peripheral blood lymphocyte count from the pretreatment baseline value, ≥ 50% reduction in lymphadenopathy, ≥ 50% reduction in size of liver and/or spleen and one of the following:&#xD;
polymorphonuclear leukocytes ≥ 1,500/μl or 50% improvement over baseline platelets &gt; 100,000/μl or 50% improvement over baseline or hemoglobin &gt; 11.0 gm/dl or 50% improvement over baseline without transfusions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients Treated With Alemtuzumab and Rituximab Combination With Response (CR or PR) Assessed by NCI-WG 1996 Criteria With Measurements of the Lymph Nodes and Spleen Size by CT Scans</measure>
    <time_frame>At week 9, and post-18 weeks then every 3 months for a year and up every 6 months for up to 2 years</time_frame>
    <description>Response rate (complete remission(CR) + partial response(PR)) will be assessed by NCI-WG 1996 criteria with measurements of the lymph nodes and spleen size by CT scans. Best response at any timepoint is captured below.&#xD;
CR= absence of significant lymphadenopathy (e.g. lymph nodes &gt; 1.5 cm in their greatest transverse diameter) and no hepatomegaly or splenomegaly.&#xD;
PR=reduction in lymphadenopathy as defined by the following: (a) a decrease in lymph node size by 50% or more either in the sum products of up to six lymph nodes, or in the largest diameter of the enlarged lymph node(s) detected prior to therapy; (b) no increase in any lymph node, and no new enlarged lymph node; in small lymph nodes (&lt; 2cm), an increase of less than 25% was not considered to be significant and a reduction in the noted pretreatment enlargement of the spleen or liver by 50% or more.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity of the Study Medications, Alemtuzumab and Rituximab</measure>
    <time_frame>During treatment, 18 weeks</time_frame>
    <description>Toxicity data will be collected at visits during 18 weeks of treatment and include adverse events considered at least possibly related to either study drugs (Alemtuzumab and Rituximab) and graded 3-5 using CTCAE 3.0.&#xD;
In general grading is as follows:&#xD;
Grade 1=mild Grade 2=moderate Grade 3=severe Grade 4=life threatening Grade 5=death Reported below are the number of patients who experienced each event</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>Alemtuzumab and Rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of Alemtuzumab combined with Rituximab to test the feasibility of combining these two monoclonal antibodies as a first line therapy in patients with B-cell chronic lymphocytic leukemia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Alemtuzumab</intervention_name>
    <description>Alemtuzumab administered subcutaneously 30mg per day, 3 days per week for 18 weeks</description>
    <arm_group_label>Alemtuzumab and Rituximab</arm_group_label>
    <other_name>Campath-1H</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Rituximab administered intravenously at 375mg/m2 every 2 weeks for 18 weeks</description>
    <arm_group_label>Alemtuzumab and Rituximab</arm_group_label>
    <other_name>Rituxan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of B-cell chronic lymphocytic leukemia (CLL)*, as defined by the following&#xD;
             criteria:&#xD;
&#xD;
               -  Peripheral blood absolute lymphocyte count &gt; 5,000/mm³&#xD;
&#xD;
               -  Small- to moderate-size lymphocytes with &lt; 55% prolymphocytes, atypical&#xD;
                  lymphocytes, or lymphoblasts&#xD;
&#xD;
               -  Phenotypically characterized B-CLL expressing CD20 and CD52, as defined by the&#xD;
                  following:&#xD;
&#xD;
                    -  Predominant population of cells share B-cell antigens with CD-5 in the&#xD;
                       absence of other pan-T-cell markers (e.g., CD-3, CD-2)&#xD;
&#xD;
                    -  B-cell expresses either lambda or kappa light chains&#xD;
&#xD;
                    -  Surface immunoglobulin with low-cell surface density expression NOTE:&#xD;
                       *Presence of splenomegaly, hepatomegaly, or lymphadenopathy are not required&#xD;
                       for the diagnosis of CLL&#xD;
&#xD;
          -  Requires therapy, as indicated by ≥ 1 of the following criteria:&#xD;
&#xD;
               -  Unintentional weight loss &gt; 10% within the past 6 months&#xD;
&#xD;
               -  Extreme fatigue (i.e., ECOG performance status 2)&#xD;
&#xD;
               -  Fevers &gt; 100.5°F for 2 weeks without evidence of infection&#xD;
&#xD;
               -  Night sweats without evidence of infection&#xD;
&#xD;
               -  Evidence of progressive marrow failure as manifested by the development of or&#xD;
                  worsening of anemia (hemoglobin &lt; 10 g/dL) and/or thrombocytopenia (platelet&#xD;
                  count &lt; 100,000/mm³)&#xD;
&#xD;
               -  Massive (i.e., &gt; 6 cm below left costal margin) or progressive splenomegaly&#xD;
&#xD;
               -  Massive nodes/clusters (&gt; 5 cm), progressive symptomatic adenopathy, or&#xD;
                  adenopathy resulting in end-organ damage&#xD;
&#xD;
               -  Progressive lymphocytosis with an increase of &gt; 50% over 2 months or an&#xD;
                  anticipated doubling time &lt; 6 months&#xD;
&#xD;
          -  Marked hypogammaglobulinemia or the development of a monoclonal protein in the absence&#xD;
             of any of the above criteria for active disease is not sufficient for eligibility&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  ANC ≥ 1,000/mm³*&#xD;
&#xD;
          -  Platelet count ≥ 50,000/mm³*&#xD;
&#xD;
          -  Hemoglobin ≥ 10 g/dL*&#xD;
&#xD;
          -  Serum creatinine ≤ 2.0 mg/dL OR creatinine clearance &gt; 40 mL/min&#xD;
&#xD;
          -  Bilirubin &lt; 2 mg/dL&#xD;
&#xD;
          -  AST and ALT ≤ 2 times normal (unless secondary to tumor infiltration/lymphadenopathy)&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 6 months after&#xD;
             completion of study treatment&#xD;
&#xD;
          -  No active autoimmune anemia or thrombocytopenia&#xD;
&#xD;
          -  No active infection requiring oral or intravenous antibiotics&#xD;
&#xD;
          -  No second malignancy, other than basal cell carcinoma of the skin or in situ carcinoma&#xD;
             of the cervix, unless curatively treated ≥ 2 years ago NOTE: *If cytopenias are due to&#xD;
             degree of bone marrow involvement, patient may be eligible at the discretion of the&#xD;
             principal investigator.&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Prior corticosteroid therapy allowed&#xD;
&#xD;
          -  No prior cytotoxic therapy (other than corticosteroids)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olga Frankfurt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University, Northwestern Medical Faculty Foundation</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>March 6, 2009</study_first_submitted>
  <study_first_submitted_qc>March 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2009</study_first_posted>
  <results_first_submitted>September 22, 2020</results_first_submitted>
  <results_first_submitted_qc>September 22, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 19, 2020</results_first_posted>
  <last_update_submitted>October 15, 2020</last_update_submitted>
  <last_update_submitted_qc>October 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>B-cell chronic lymphocytic leukemia</keyword>
  <keyword>stage I chronic lymphocytic leukemia</keyword>
  <keyword>stage II chronic lymphocytic leukemia</keyword>
  <keyword>stage III chronic lymphocytic leukemia</keyword>
  <keyword>stage IV chronic lymphocytic leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Alemtuzumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study opened for accrual on 29th March 2005 with the first patient starting treatment 26th September 2005 and an accrual goal of 30 patients. The study closed to further enrollment on the 26th October 2009 with 30 patients treated on study.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Alemtuzumab and Rituximab</title>
          <description>Administration of Alemtuzumab combined with Rituximab to test the feasibility of combining these two monoclonal antibodies as a first line therapy in patients with B-cell chronic lymphocytic leukemia.&#xD;
Alemtuzumab: Alemtuzumab administered subcutaneously 30mg per day, 3 days per week for 18 weeks&#xD;
Rituximab: Rituximab administered intravenously at 375mg/m2 every 2 weeks (starting week 3) for 18 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment on Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed 18 Weeks of Treatment</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Follow up for 5 Years</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30">All patients who receive at least one dose of drug under the protocol go into follow up for survival</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No further data collected for study</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Alemtuzumab and Rituximab</title>
          <description>Administration of Alemtuzumab combined with Rituximab to test the feasibility of combining these two monoclonal antibodies as a first line therapy in patients with B-cell chronic lymphocytic leukemia.&#xD;
Alemtuzumab: Alemtuzumab administered subcutaneously 30mg per day, 3 days per week for 18 weeks&#xD;
Rituximab: Rituximab administered intravenously at 375mg/m2 every 2 weeks (starting week 3) for 18 weeks</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Treated With Alemtuzumab and Rituximab Combination With a Response (CR or PR) Assessed by NCI-WG 1996 Criteria With Lymph-adenopathy and Organomegaly Measured During Physical Examination</title>
        <description>Response rate (complete remission(CR) + partial remission(PR)) will be, assessed by NCI-WG 1996 criteria with lymphadenopathy and organomegaly measured during physical examination.&#xD;
CR=Absence of lymphadenopathy and constitutional symptoms, Normal CBC (leukocytes ≥ 1500/μl, Platelets &gt;100,000/μl, Hemoglobin &gt; 11.0 gm/dl), peripheral blood lymphocytes ≤ 4,000/μl.The marrow sample must be at least normocellular with &lt; 30% of nucleated cells being lymphocytes.&#xD;
PR=absence of constitutional symptoms, ≥ 50% decrease in peripheral blood lymphocyte count from the pretreatment baseline value, ≥ 50% reduction in lymphadenopathy, ≥ 50% reduction in size of liver and/or spleen and one of the following:&#xD;
polymorphonuclear leukocytes ≥ 1,500/μl or 50% improvement over baseline platelets &gt; 100,000/μl or 50% improvement over baseline or hemoglobin &gt; 11.0 gm/dl or 50% improvement over baseline without transfusions</description>
        <time_frame>At week 9, and post-18 weeks then every 3 months for a year and up every 6 months for up to 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Alemtuzumab and Rituximab</title>
            <description>Administration of Alemtuzumab combined with Rituximab to test the feasibility of combining these two monoclonal antibodies as a first line therapy in patients with B-cell chronic lymphocytic leukemia.&#xD;
Alemtuzumab: Alemtuzumab administered subcutaneously 30mg per day, 3 days per week for 18 weeks&#xD;
Rituximab: Rituximab administered intravenously at 375mg/m2 every 2 weeks (starting week 3) for 18 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Treated With Alemtuzumab and Rituximab Combination With a Response (CR or PR) Assessed by NCI-WG 1996 Criteria With Lymph-adenopathy and Organomegaly Measured During Physical Examination</title>
          <description>Response rate (complete remission(CR) + partial remission(PR)) will be, assessed by NCI-WG 1996 criteria with lymphadenopathy and organomegaly measured during physical examination.&#xD;
CR=Absence of lymphadenopathy and constitutional symptoms, Normal CBC (leukocytes ≥ 1500/μl, Platelets &gt;100,000/μl, Hemoglobin &gt; 11.0 gm/dl), peripheral blood lymphocytes ≤ 4,000/μl.The marrow sample must be at least normocellular with &lt; 30% of nucleated cells being lymphocytes.&#xD;
PR=absence of constitutional symptoms, ≥ 50% decrease in peripheral blood lymphocyte count from the pretreatment baseline value, ≥ 50% reduction in lymphadenopathy, ≥ 50% reduction in size of liver and/or spleen and one of the following:&#xD;
polymorphonuclear leukocytes ≥ 1,500/μl or 50% improvement over baseline platelets &gt; 100,000/μl or 50% improvement over baseline or hemoglobin &gt; 11.0 gm/dl or 50% improvement over baseline without transfusions</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Treated With Alemtuzumab and Rituximab Combination With Response (CR or PR) Assessed by NCI-WG 1996 Criteria With Measurements of the Lymph Nodes and Spleen Size by CT Scans</title>
        <description>Response rate (complete remission(CR) + partial response(PR)) will be assessed by NCI-WG 1996 criteria with measurements of the lymph nodes and spleen size by CT scans. Best response at any timepoint is captured below.&#xD;
CR= absence of significant lymphadenopathy (e.g. lymph nodes &gt; 1.5 cm in their greatest transverse diameter) and no hepatomegaly or splenomegaly.&#xD;
PR=reduction in lymphadenopathy as defined by the following: (a) a decrease in lymph node size by 50% or more either in the sum products of up to six lymph nodes, or in the largest diameter of the enlarged lymph node(s) detected prior to therapy; (b) no increase in any lymph node, and no new enlarged lymph node; in small lymph nodes (&lt; 2cm), an increase of less than 25% was not considered to be significant and a reduction in the noted pretreatment enlargement of the spleen or liver by 50% or more.</description>
        <time_frame>At week 9, and post-18 weeks then every 3 months for a year and up every 6 months for up to 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Alemtuzumab and Rituximab</title>
            <description>Administration of Alemtuzumab combined with Rituximab to test the feasibility of combining these two monoclonal antibodies as a first line therapy in patients with B-cell chronic lymphocytic leukemia.&#xD;
Alemtuzumab: Alemtuzumab administered subcutaneously 30mg per day, 3 days per week for 18 weeks&#xD;
Rituximab: Rituximab administered intravenously at 375mg/m2 every 2 weeks (starting week 3) for 18 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Treated With Alemtuzumab and Rituximab Combination With Response (CR or PR) Assessed by NCI-WG 1996 Criteria With Measurements of the Lymph Nodes and Spleen Size by CT Scans</title>
          <description>Response rate (complete remission(CR) + partial response(PR)) will be assessed by NCI-WG 1996 criteria with measurements of the lymph nodes and spleen size by CT scans. Best response at any timepoint is captured below.&#xD;
CR= absence of significant lymphadenopathy (e.g. lymph nodes &gt; 1.5 cm in their greatest transverse diameter) and no hepatomegaly or splenomegaly.&#xD;
PR=reduction in lymphadenopathy as defined by the following: (a) a decrease in lymph node size by 50% or more either in the sum products of up to six lymph nodes, or in the largest diameter of the enlarged lymph node(s) detected prior to therapy; (b) no increase in any lymph node, and no new enlarged lymph node; in small lymph nodes (&lt; 2cm), an increase of less than 25% was not considered to be significant and a reduction in the noted pretreatment enlargement of the spleen or liver by 50% or more.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Toxicity of the Study Medications, Alemtuzumab and Rituximab</title>
        <description>Toxicity data will be collected at visits during 18 weeks of treatment and include adverse events considered at least possibly related to either study drugs (Alemtuzumab and Rituximab) and graded 3-5 using CTCAE 3.0.&#xD;
In general grading is as follows:&#xD;
Grade 1=mild Grade 2=moderate Grade 3=severe Grade 4=life threatening Grade 5=death Reported below are the number of patients who experienced each event</description>
        <time_frame>During treatment, 18 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Alemtuzumab and Rituximab</title>
            <description>Administration of Alemtuzumab combined with Rituximab to test the feasibility of combining these two monoclonal antibodies as a first line therapy in patients with B-cell chronic lymphocytic leukemia.&#xD;
Alemtuzumab: Alemtuzumab administered subcutaneously 30mg per day, 3 days per week for 18 weeks&#xD;
Rituximab: Rituximab administered intravenously at 375mg/m2 every 2 weeks (starting week 3) for 18 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Toxicity of the Study Medications, Alemtuzumab and Rituximab</title>
          <description>Toxicity data will be collected at visits during 18 weeks of treatment and include adverse events considered at least possibly related to either study drugs (Alemtuzumab and Rituximab) and graded 3-5 using CTCAE 3.0.&#xD;
In general grading is as follows:&#xD;
Grade 1=mild Grade 2=moderate Grade 3=severe Grade 4=life threatening Grade 5=death Reported below are the number of patients who experienced each event</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Neutropenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thrombocytopenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Renal toxicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Best Response in Patients Treated With Alemtuzumab and Rituximab Combination Assessed by NCI-WG 1996 Criteria With Lymphadenopathy and Organomegaly Measured During Physical Examination</title>
        <description>Patients best response to treatment as defined in general as:&#xD;
Complete Remission=Absence of lymphadenopathy and constitutional symptoms, Normal CBC, peripheral blood lymphocytes ≤ 4,000/μl.The marrow sample must be at least normocellular with &lt; 30% of nucleated cells being lymphocytes.&#xD;
Partial Remission=absence of constitutional symptoms, ≥50%decrease in peripheral blood lymphocyte count, ≥50%reduction in lymphadenopathy, ≥50%reduction in liver and/or spleen size &amp; 1 of the following:&#xD;
polymorphonuclear leukocytes ≥ 1,500/μl or 50% improvement over baseline, platelets &gt;100,000/μl or 50%improvement over baseline, hemoglobin &gt; 11.0 gm/dl or 50% improvement over baseline without transfusions. Stable Disease=Do not meet criteria for complete/partial remission or progressive disease.&#xD;
Progressive Disease= ≥50%increase ≥2 lymph nodes or ≥50% increase in absolute no. of circulating lymphocytes or ≥50% increase in liver and/or spleen size or transformation to a more aggressive histology</description>
        <time_frame>At week 9, and post 18 weeks of treatment, then every 3 months for a year and up every 6 months for up to 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Alemtuzumab and Rituximab</title>
            <description>Administration of Alemtuzumab combined with Rituximab to test the feasibility of combining these two monoclonal antibodies as a first line therapy in patients with B-cell chronic lymphocytic leukemia.&#xD;
Alemtuzumab: Alemtuzumab administered subcutaneously 30mg per day, 3 days per week for 18 weeks&#xD;
Rituximab: Rituximab administered intravenously at 375mg/m2 every 2 weeks (starting week 3) for 18 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Best Response in Patients Treated With Alemtuzumab and Rituximab Combination Assessed by NCI-WG 1996 Criteria With Lymphadenopathy and Organomegaly Measured During Physical Examination</title>
          <description>Patients best response to treatment as defined in general as:&#xD;
Complete Remission=Absence of lymphadenopathy and constitutional symptoms, Normal CBC, peripheral blood lymphocytes ≤ 4,000/μl.The marrow sample must be at least normocellular with &lt; 30% of nucleated cells being lymphocytes.&#xD;
Partial Remission=absence of constitutional symptoms, ≥50%decrease in peripheral blood lymphocyte count, ≥50%reduction in lymphadenopathy, ≥50%reduction in liver and/or spleen size &amp; 1 of the following:&#xD;
polymorphonuclear leukocytes ≥ 1,500/μl or 50% improvement over baseline, platelets &gt;100,000/μl or 50%improvement over baseline, hemoglobin &gt; 11.0 gm/dl or 50% improvement over baseline without transfusions. Stable Disease=Do not meet criteria for complete/partial remission or progressive disease.&#xD;
Progressive Disease= ≥50%increase ≥2 lymph nodes or ≥50% increase in absolute no. of circulating lymphocytes or ≥50% increase in liver and/or spleen size or transformation to a more aggressive histology</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Complete Remission</title>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Partial Remission</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Stable Disease</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Progressive Disease</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Best Response in Patients Treated With Alemtuzumab and Rituximab Combination Assessed by NCI-WG 1996 Criteria With Measurements of the Lymph Nodes and Spleen Size by CT Scans</title>
        <description>Best Response to treatment, in general is defined as:&#xD;
Complete Remission= absence of significant lymphadenopathy and no hepatomegaly/splenomegaly.&#xD;
Partial Remission=reduction in lymphadenopathy as defined by the following: (a) 50% decrease in lymph node size by 50% either in the sum products of up to six lymph nodes, or in the largest diameter of the enlarged lymph node(s) detected prior to therapy; (b) no increase in any lymph node, and no new enlarged lymph node; in small lymph nodes (&lt;2cm),and a reduction in the noted pretreatment enlargement of the spleen or liver by 50% or more.&#xD;
Stable Disease=not meet criteria for complete/partial remission or progressive disease Progressive Disease=appearance of any new lesion, such as enlarged lymph nodes (1.5cm), splenomegaly, hepatomegaly or other organ infiltrates: (a)50%increase + in greatest diameter of any previous site; (b)50% + increase liver or spleen size.</description>
        <time_frame>At week 9, and post-18 weeks then every 3 months for a year and up every 6 months for up to 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Alemtuzumab and Rituximab</title>
            <description>Administration of Alemtuzumab combined with Rituximab to test the feasibility of combining these two monoclonal antibodies as a first line therapy in patients with B-cell chronic lymphocytic leukemia.&#xD;
Alemtuzumab: Alemtuzumab administered subcutaneously 30mg per day, 3 days per week for 18 weeks&#xD;
Rituximab: Rituximab administered intravenously at 375mg/m2 every 2 weeks (starting week 3) for 18 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Best Response in Patients Treated With Alemtuzumab and Rituximab Combination Assessed by NCI-WG 1996 Criteria With Measurements of the Lymph Nodes and Spleen Size by CT Scans</title>
          <description>Best Response to treatment, in general is defined as:&#xD;
Complete Remission= absence of significant lymphadenopathy and no hepatomegaly/splenomegaly.&#xD;
Partial Remission=reduction in lymphadenopathy as defined by the following: (a) 50% decrease in lymph node size by 50% either in the sum products of up to six lymph nodes, or in the largest diameter of the enlarged lymph node(s) detected prior to therapy; (b) no increase in any lymph node, and no new enlarged lymph node; in small lymph nodes (&lt;2cm),and a reduction in the noted pretreatment enlargement of the spleen or liver by 50% or more.&#xD;
Stable Disease=not meet criteria for complete/partial remission or progressive disease Progressive Disease=appearance of any new lesion, such as enlarged lymph nodes (1.5cm), splenomegaly, hepatomegaly or other organ infiltrates: (a)50%increase + in greatest diameter of any previous site; (b)50% + increase liver or spleen size.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Complete Remission</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Partial Remission</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Stable Disease</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Progressive Disease</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Patients were assessed for adverse events (including serious adverse event (SAE) due to hospitalizations) and data was collected, from the time of treatment initiation through 18 weeks of treatment. All cause mortality was collected during 18 weeks of treatment and through 5 years of follow up. Additionally, new cancer SAEs were collected through treatment and through 5 years of follow up.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Alemtuzumab and Rituximab</title>
          <description>Administration of Alemtuzumab combined with Rituximab to test the feasibility of combining these two monoclonal antibodies as a first line therapy in patients with B-cell chronic lymphocytic leukemia.&#xD;
Alemtuzumab: Alemtuzumab administered subcutaneously 30mg per day, 3 days per week for 18 weeks&#xD;
Rituximab: Rituximab administered intravenously at 375mg/m2 every 2 weeks (starting week 3) for 18 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE 3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Possible infection with fever</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Chronic myelogenous leukemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Diffuse large B cell lymphoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Multiple myeoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Urachal adenocarcinoma of the bladder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Esophageal cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Colon Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Possible acute renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE 3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin (anemia)</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Neutrophils (neutropenia)</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Leukocytes (total WBC)</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Platelets (thrombocytopenia)</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>:Edema:trunk/genital</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pressure/pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Pain : ear</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flashes/flushes</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Flashing lights</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Watery eye (epiphora, tearing)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Heartburn/dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Dry lips</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Taste alteration(dysgeusia)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Scratchy throat</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Dysphagia (difficulty swallowing)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Abdomen pain NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic rhinitis (including sneezing,nasal stuffiness,postnasal drip)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Rigors</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Shaking</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>GENERAL- Pain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Flu-like syndrome</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Nasal drip</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Lung (pneumonia)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Upper airway infection NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Adenovirus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>CMV positive</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Transaminase</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Bicarbinate high</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>High GFR</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>ALT, SGPT (serum glutamic pyruvic transaminase)high</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>AST, SGOT (serum glutamic oxaloacetic transaminase) high</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Albumin, serum-low (hypoalbuminemia)</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Bilirubin (hyperbilirubinemia)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>High LDH</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Increased BUN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Calcium, serum-low (hypocalcemia)</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Cholesterol, serum-high (hypercholesteremia)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Glucose, serum-high (hyperglycemia)</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Glucose, serum-low(hypoglycemia)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Magnesium, serum-high (hypermagnesemia)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Magnesium, serum-low(hypomagnesemia)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Phosphate, serum-low (hypophosphatemia)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Potassium, serum-high(hyperkalemia)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Potassium, serum-low(hypokalemia)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Sodium, serum-high(hypernatremia)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Sodium, serum-low(hyponatremia)</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Uric acid, serum-high (hyperuricemia)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle aches</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Muscle cramps</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Leg cramps</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy:sensory</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Motor - hand tremors</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Syncope (fainting)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Mood alteration - Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Mood alteration - Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Polyuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Renal incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Renal insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>vaginal burning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Dyspnea on exertion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site reaction/extravasation changes</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Pruritus/itching</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Perivascular neutrophilic dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Sun burn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Skin peeling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hives</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Blotchiness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Olga Frankfurt, MD</name_or_title>
      <organization>Northwestern University</organization>
      <phone>312 695 6180</phone>
      <email>o-frankfurt@northwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

